While CD19-CAR-T therapy effectively controls tumor cells in patients with acute lymphoblastic leukemia (ALL), depending on the CAR constructs and manufacturing, there are severe toxicities in a subset of patients, such as cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS).13 Here, CD19 is linked to acute lymphoblastic leukemia.